The Influence of Surgical Complexity and Center Experience on Postoperative Morbidity After Minimally Invasive Surgery in Gynecologic Oncology: Lessons Learned from the ROBOGYN-1004 Trial
  • Clinic

The Influence of Surgical Complexity and Center Experience on Postoperative Morbidity After Minimally Invasive Surgery in Gynecologic Oncology: Lessons Learned from the ROBOGYN-1004 Trial

A co-culture system of macrophages with breast cancer tumoroids to study cell interactions and therapeutic responses
  • Recherche

A co-culture system of macrophages with breast cancer tumoroids to study cell interactions and therapeutic responses

A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off
  • Recherche

A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off

Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
  • Clinic

Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer

Enhancer of Zeste Homolog 2 Inhibition Induces HLA Class I Re-Expression in Merkel Cell Carcinoma
  • Recherche

Enhancer of Zeste Homolog 2 Inhibition Induces HLA Class I Re-Expression in Merkel Cell Carcinoma

Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial
  • Clinic

Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial

CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas
  • Clinic

CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas

Complex abdominal wall reconstruction for an isolated parietal recurrence of ovarian cancer
  • Clinic

Complex abdominal wall reconstruction for an isolated parietal recurrence of ovarian cancer

Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France
  • Clinic

Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France

OpenProt 2.0 builds a path to the functional characterization of alternative proteins
  • Recherche

OpenProt 2.0 builds a path to the functional characterization of alternative proteins

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review
  • Clinic

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review

Real-time glioblastoma tumor microenvironment assessment by SpiderMass for improved patient management
  • Recherche

Real-time glioblastoma tumor microenvironment assessment by SpiderMass for improved patient management